FDA clears Amgen’s Prolia for glucocorticoid osteoporosis
US regulators have approved a new indication for Amgen’s Prolia, allowing its use to treat glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture.
Read More
Tag: denosumab
AZ’ lung cancer drug Tagrisso backed for first-line use
European regulatory advisors are supporting approval of AstraZeneca’s lung cancer drug Tagrisso in the first-line setting.
Read More
EU expands scope of Amgen’s Xgeva
European regulators have expanded the treatment scope of Amgen’s Xgeva to include the prevention of skeletal-related events in adults with multiple myeloma.
Read More
Amgen’s Xgeva cleared for multiple myeloma patients
US regulators have expanded the scope of Amgen’s Xgeva to include the prevention of skeletal-related events in patients with multiple myeloma.
Read More
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
